

E-Selectin inhibitor– Pipeline Insight, 2022

<https://marketpublishers.com/r/P809DF06422EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P809DF06422EN

Abstracts

This report can be delivered to the clients within 48 hrs

DelveInsight's, "E-Selectin inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 4+ companies and 7+ pipeline drugs in E-selectin inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

E-Selectin inhibitor Understanding

E-SELECTIN inhibitor: Overview

E-Selectin (CD62E or previously referred to as ELAM-1) is a 115 kDa, inducible endothelial cell surface molecule. Its expression on endothelial cells is transcriptionally upregulated by various proinflammatory substances such as IL-1, TNF α and lipopolysaccharide (LPS). Expression of E-selectin on the endothelium is a hallmark of inflammation. E-selectin has been chosen as a target for several therapeutic and medical imaging applications, based on its expression in the vicinity of inflammation, infection or cancer.

Structure- E-selectin is a transmembrane receptor of the selectin family that also contains L- and P-selectins. Two glycosylated forms of E-selectin are detected at 100

and 115 kDa. The primary structure of E-selectin contains several domains: an amino terminal lectin-like domain, followed by an epidermal growth factor (EGF)-like domain and six repeated motifs similar to those found in some complement-binding proteins.

Function – E-Selectin is involved in the accumulation process of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.

E-SELECTIN Inhibitors- In research studies, Inhibiting E-selectin attenuated inflammation in atherosclerotic plaques, likely by reducing leukocyte recruitment into plaques and by mitigating hematopoietic stem and progenitor cell activation in the spleen of mice with myocardial Infarction. Various strategies are studied to exploit and modulate E-selectin-mediated binding include blocking its interaction with its ligands, blocking its ligands and inhibiting the glycosyl transferases associated with biosynthesis of selectin carbohydrate binding determinants. These strategies could inhibit immune and cancer cell adhesion in inflammation and metastasis, respectively.

E-SELECTIN inhibitor Emerging Drugs Chapters

This segment of the E-SELECTIN inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

E-SELECTIN inhibitor Emerging Drugs

Uproleselan: GlycoMimetics

A specific E-selectin antagonist, Uproleselan is an investigational small molecule with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. In combination with chemotherapy, uproleselan is used to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers. The drug is currently in Phase III clinical studies for acute myeloid leukaemia.

PF-07209326: Pfizer

PF-07209326 is an investigational biological therapy as E-Selectin antagonist. The therapy is currently in Phase I clinical development for the treatment of Sickle Cell disease.

Further product details are provided in the report.....

E-SELECTIN inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different E-SELECTIN inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on E-SELECTIN inhibitor

There are approx. 4+ key companies which are developing the E-SELECTIN inhibitor. The companies which have their E-SELECTIN inhibitor drug candidates in the most advanced stage, i.e. Phase III include, GlycoMimetics.

Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

E-SELECTIN inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

E-SELECTIN inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses E-SELECTIN inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging E-SELECTIN inhibitor drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence E-SELECTIN inhibitor R&D. The therapies under development are focused on novel approaches for E-SELECTIN inhibitor.

In January 2020, GlycoMimetics and Apollomics announce exclusive collaboration and license agreement to develop and commercialize uproleselan and GMI-1687 in Greater China. Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties.

E-SELECTIN inhibitor Report Insights

E-SELECTIN inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

E-SELECTIN inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing E-SELECTIN inhibitor drugs?

How many E-SELECTIN inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for E-SELECTIN inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the E-SELECTIN inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for E-SELECTIN inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

GlycoMimetics

Modus Therapeutics

Pfizer

Key Products

Uproleselan

Rivipansel

Sevuparin

GMI-1687

GMI-1359

PF-07209326

Contents

- Introduction
- Executive Summary
- E-SELECTIN inhibitor: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- E-SELECTIN inhibitor – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - E-SELECTIN inhibitor companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- E-SELECTIN inhibitor Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Uproleselan: GlycoMimetics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- PF-07209326: Pfizer
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
 - Comparative Analysis

GMI-1687: GlycoMimetics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

E-SELECTIN inhibitor Key Companies

E-SELECTIN inhibitor Key Products

E-SELECTIN inhibitor- Unmet Needs

E-SELECTIN inhibitor- Market Drivers and Barriers

E-SELECTIN inhibitor- Future Perspectives and Conclusion

E-SELECTIN inhibitor Analyst Views

E-SELECTIN inhibitor Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for E-SELECTIN inhibitor
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for E-SELECTIN inhibitor
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: E-Selectin inhibitor– Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P809DF06422EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P809DF06422EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970